57% were female, mean (±SD) age was 55.71 (18.86) years, and all patients had ≥1 recorded GI-specific morbidity. Results: To date, data on 22 bleeds in 7 patients with type 1 (14%), type 2 (43%) or type 3 (43%) have been abstracted. prophylaxis, on-demand rVWF, plasma-derived VWF) at the time of a GI bleed and for any subsequent period of prophylactic treatment to prevent GI bleed recurrence. Clinical effectiveness will be defined by treatment response, change in duration of treatment or time to bleed resolution across treatment cohorts (e.g. Demographics and clinical information, including treatment regimens, will be abstracted from patient records on all recorded GI bleeds within the last 5 years. The target sample size is 20 patients from 6 US centers. Methods: This retrospective, multicenter, observational chart review included patients with confirmed congenital VWD with ≥1 GI bleed within last 5 years (abstraction initiated 2019 and ongoing). Despite von Willebrand Factor (VWF) replacement therapy, GI bleeding may be refractory resulting in various treatment approaches with no consensus regarding the most effective therapeutic approach.Īims: To describe etiology and management of GI bleeds, and outcomes following VWF replacement products and adjuvant therapy, including recombinant VWF (rVWF). Theme: Platelet Disorders and von Willebrand Disease » VWF and von Willebrand Factor Disorders - Clinical Conditionsīackground: Specific etiology and treatment of gastrointestinal (GI) bleeds in patients with von Willebrand disease (VWD) is challenging and compounded by limited published data.

Retrospective chart review